When choosing a biomaterial, there is a strong demand in clinical practice for predictable outcomes. For over 20 years, LifeCell™, an Allergan affiliate and leading global medical technology company, has developed innovative products for use in a wide range of applications.
BioHorizons Camlog expands its soft-tissue portfolio in partnership with LifeCell™ to bring NovoMatrix™, the next generation of soft-tissue augmentation material, into the European market. Full market release of this product will take place at the Oral Reconstruction Foundation Symposium in New York City in April 2020.
What is NovoMatrix™?
NovoMatrix™ is an acellular extracellular dermal matrix consisting of tissue-engineered porcine material. NovoMatrix™ is a breakthrough in xenogenic processing ensuring a structurally intact, undamaged scaffold that supports cell and microvascular ingrowth. The proprietary tissue processing allows for rapid revascularization, cell repopulation and minimal inflammation. NovoMatrix™ comes pre-hydrated and ready to use and offers a true alternative to autogenous soft-tissue grafts and current products on the market.
Indications and clinical evidence
The NovoMatrix™ indications include guided tissue regeneration procedures in recession defects for root coverage, localized gingival augmentation to increase keratinized tissue (KT) around teeth and alveolar ridge reconstruction for prosthetic treatment. Dr Edward Pat Allen, one of the pioneer users of NovoMatrix™, says: “NovoMatrix™ graft exhibits uniform physical characteristics and great surgical handling, enhancing its ease of use in the tunnelling technique. This results in an excellent clinical outcome with minimal post-operative swelling and inflammation.”
“NovoMatrix™ represents a significant addition to our soft-tissue product portfolio,” said Steve Boggan, President and CEO of BioHorizons. “We now offer our customers a differentiated alternative to connective tissue for applications such as root coverage and soft-tissue augmentation around implants and natural teeth.”
At this year’s Osteology Symposium, BioHorizons and Camlog will display their complete product line-up and will also be sponsoring a hands-on workshop on Thursday, May 25th on “Novel regenerative concepts using dermal matrices- from integration to regeneration” with Dr Edward P. Allen. In the afternoon of the same day, Dr Gerhard Iglhaut will discuss “Innovative treatment concepts on how to improve efficiency and regeneration” during the corporate forum. Furthermore, at booth #5 during coffee and lunch breaks, BioHorizons and Camlog’s team of experts invite clinicians to participate in interactive demonstrations featuring the PROGRESSIVE line implants, which was recently launched, as well as NovoMatrix™, led by Dr. Edward P. Allen.
About BioHorizons and Camlog
BioHorizons and Camlog are leading suppliers of premium dental implant systems, restorative components, a comprehensive line of biologics products and digital solutions. They are committed to developing evidence-based and scientifically proven products as well as offering continuous education according to highest standards.
Headquartered in the U.S. and Europe, respectively, BioHorizons and Camlog’s geographic positions enable them to efficiently serve direct subsidiaries in the Americas and Western Europe as well as their entire distribution network in more than 90 countries around the world.
Both companies are part of Henry Schein, Inc., a solutions company for health care professionals powered by a network of people and technology. With more than 18,000 Team Schein Members worldwide, Henry Schein’s network of trusted advisors provides over 1 million customers globally with more than 300 valued solutions improving operational success and clinical outcomes. The Company’s business, clinical, technology, and supply chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.
For more information, visit www.biohorizons.com, www.camlog.com and www.henryschein.com.